Biotechnology company Vect-Horus has signed a global licence agreement with Novo Nordisk for the development of targeted therapeutics.
The agreement grants Novo Nordisk an exclusive worldwide licence to utilise Vect-Horus’s VECTrans platform technology for delivering cargo aimed at specific targets.
Vect-Horus co-founder and CEO Alexandre Tokay stated: “This agreement is another important step in our strategy to establish commercial partnerships and to secure significant short-term cash to implement our technology and development programmes.
“We look forward to collaborating with Novo Nordisk to unlock the potential of our technology platform and develop more efficient treatments.”
Vect-Horus will be eligible for an upfront payment and has the option to earn up to $327m in additional developmental, regulatory and commercial milestones across three programmes, along with receiving €40m in subsidies and equity.
The company will also receive tiered royalties on sales of the products.
Access the most comprehensive Company Profiles
on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Company Profile – free
sample
Thank you!
Your download email will arrive shortly
We are confident about the
unique
quality of our Company Profiles. However, we want you to make the most
beneficial
decision for your business, so we offer a free sample that you can download by
submitting the below form
By GlobalData
Novo Nordisk Global Research Technologies senior vice-president Brian Vandahl stated: “We are thrilled to work with Vect-Horus by leveraging their platform to discover optimal delivery for specified targets.
“It is an exemplary opportunity for us to utilise external collaboration to further fuel our own innovation processes, with a common goal of improving health outcomes.”
Vect-Horus is focused on the design and development of vectors that enable targeting and delivery of imaging or therapeutic agents to organs, including the brain, and to tumours.
Source link
#VectHorus #Novo #Nordisk #partner #therapeutics #development
